Acorda is exploring several therapeutic approaches that may help restore function or repair nerve connections in the central nervous system.
- Neuregulins – This program is applying Glial Growth Factor 2 (GGF2), a neuregulin growth factor, to stimulate repair in both the nervous and cardiac systems. In published studies in preclinical models, GGF2 has been shown to protect the brain from the consequences of stroke and to stimulate remyelination in models of MS. In addition, neuregulins have shown the ability to restore cardiac function and improve survival in preclinical models of heart failure caused by myocardial infarction, rapid pacing, and viral and chemically induced cardiomyopathies.
Acorda has initiated a Phase 1 single-dose clinical trial of GGF2 in patients with heart failure. The Company is also continuing preclinical studies of potential neurology indications for GGF2 and other neuregulin growth factors.
- Remyelinating antibodies – Studies have demonstrated the ability of this family of antibodies to stimulate remyelination in three different preclinical models of MS. Currently, there is no approved therapy that repairs the lost or damaged myelin in demyelinating diseases such as MS.
- Chondroitinase – This program is based on breaking down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. Published research has demonstrated that this scar matrix is partly responsible for limiting the regeneration of nerve fibers in the CNS and restricting their ability to modify existing neural connections. Independent academic laboratories have also published preclinical studies showing that application of chondroitinase can result in recovery of function following injuries to various areas of the brain and spinal cord.